UT-MD Anderson Cancer Center: AACR - Novel Allogeneic CAR T Cell Therapy Delivers Promising Early Results in Patients With Metastatic Clear Cell Renal Cell Carcinoma
April 18, 2023
April 18, 2023
HOUSTON, Texas, April 18 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Phase I study of CD70-targeting therapy ALLO-316 represents progress in adapting cell therapies for solid tumors
* * *
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal . . .
* * *
Phase I study of CD70-targeting therapy ALLO-316 represents progress in adapting cell therapies for solid tumors
* * *
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal . . .